Figure 1.
Figure 1. Comparison of clonal architectures in PB vs BM samples. Each panel contains pairwise analysis of the VAF (the ratio of the variant reads vs total reads) in the PB and BM. (A) The 2 purple lines represent variants in miR142. *Indicates variants with evidence of loss of heterozygosity or copy number changes. NI, normal; SD, stable disease. (B) Del, deletion; PD, progressive disease. (C) CR, complete remission. (D) CR. (E) CRi, complete remission with incomplete count recovery; WBC, white blood cell. (F) mCR (HI PMN/Plts), marrow complete remission with hematologic improvement in neutrophils and platelets. Days, number of days since starting decitabine.

Comparison of clonal architectures in PB vs BM samples. Each panel contains pairwise analysis of the VAF (the ratio of the variant reads vs total reads) in the PB and BM. (A) The 2 purple lines represent variants in miR142. *Indicates variants with evidence of loss of heterozygosity or copy number changes. NI, normal; SD, stable disease. (B) Del, deletion; PD, progressive disease. (C) CR, complete remission. (D) CR. (E) CRi, complete remission with incomplete count recovery; WBC, white blood cell. (F) mCR (HI PMN/Plts), marrow complete remission with hematologic improvement in neutrophils and platelets. Days, number of days since starting decitabine.

Close Modal

or Create an Account

Close Modal
Close Modal